Top

27-03-2024 | Parkinson's Disease | Review Article

Exosomal microRNAs in Parkinson’s disease: insights into biomarker potential and disease pathology

Abstract

Parkinson’s disease (PD) is a prevalent neurodegenerative condition primarily affecting the elderly population. Despite its high incidence in aged individuals, there are no reliable blood-based biomarkers for clinical diagnosis of PD and early screening of susceptible individuals. Recent studies have revealed the significance of exosomes in mediating cell-to-cell communications by transferring bioactive molecules, such as proteins, nucleic acids (including miRNAs), lipids, and metabolites, between cells. Due to their ability to carry diverse molecular cargo and their involvement in various physiological and pathological processes, exosomes have gained significant attention as potential disease biomarkers. Notably, exosomes have the ability to cross the blood–brain barrier, and as a result, they can be found in circulating body fluids, including cerebrospinal fluid (CSF), serum, and plasma. Therefore, the identification of PD-specific exosomes in blood samples could be a promising avenue with biomarker potential for advancing clinical diagnosis and planning therapeutic strategies. This review highlights the current understanding of exosomal miRNAs in PD pathology, emphasising their potential for clinical utility as biomarkers even though several challenges may have to be overcome to precisely utilize exosomal miRNAs as biomarkers specific to PD.

Brooks DJ (1998) The early diagnosis of Parkinson’s disease. Ann Neurol 44:S10–S18. https://doi.org/10.1002/ana.410440704CrossRefPubMed

Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z (2021) Global trends in the incidence, Prevalence, and years lived with disability of parkinson’s disease in 204 Countries/Territories From 1990 to 2019. Front Public Health 9:776847. https://doi.org/10.3389/fpubh.2021.776847CrossRefPubMedPubMedCentral

Kramer ML, Schulz-Schaeffe WJ (2007) Presynaptic α-Synuclein Aggregates, Not lewy bodies, Cause neurodegeneration in dementia with lewy bodies. J Neurosci 27:1405–1410. https://doi.org/10.1523/JNEUROSCI.4564-06.2007CrossRefPubMedPubMedCentral

Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188:1157–1165. https://doi.org/10.1503/cmaj.151179CrossRefPubMedPubMedCentral

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184. https://doi.org/10.1136/jnnp.55.3.181CrossRefPubMedPubMedCentral

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function, and decay. Nat Rev Genet 11:597–610. https://doi.org/10.1038/nrg2843CrossRefPubMed

Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20. https://doi.org/10.1016/j.cell.2004.12.035CrossRefPubMed

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233. https://doi.org/10.1016/j.cell.2009.01.002CrossRefPubMedPubMedCentral

10.

Grimson A, Farh KKH, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91–105. https://doi.org/10.1016/j.molcel.2007.06.017CrossRefPubMedPubMedCentral

11.

Chen L, Yang J, Lü J, Cao S, Zhao Q, Yu Z (2018) Identification of aberrant circulating miRNAs in Parkinson’s disease plasma samples. Brain Behav 8:e00941. https://doi.org/10.1002/brb3.941CrossRefPubMedPubMedCentral

12.

Hoye M, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S et al (2018) Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain J Neurol 141:2561–2575. https://doi.org/10.1093/brain/awy182CrossRef

13.

Margis R, Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinsońs disease. J Biotechnol 152:96–101. https://doi.org/10.1016/j.jbiotec.2011.01.023CrossRefPubMed

14.

Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T et al (2014) Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and parkinson’s diseases correlate with disease status and features of pathology. PLoS ONE 9:e94839. https://doi.org/10.1371/journal.pone.0094839CrossRefPubMedPubMedCentral

15.

Vallelunga A, Ragusa M, Di Mauro S, Iannitti T, Pilleri M, Biundo R et al (2014) Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and Multiple System Atrophy. Front Cell Neurosci 8:156. https://doi.org/10.3389/fncel.2014.00156CrossRefPubMedPubMedCentral

16.

Ma W, Li Y, Wang C, Xu F, Liu WM, Y, (2016) Serum miR-221 serves as a biomarker for Parkinson’s disease. Cell Biochem Funct 34:511–515. https://doi.org/10.1002/cbf.3224CrossRefPubMed

17.

Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RA, Bloem BR, Verbeek MM (2017) MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson’s disease and multiple system atrophy. Mol Neurobiol 54:7736–7745. https://doi.org/10.1007/s12035-016-0253-0CrossRefPubMed

18.

Chen Y, Gao C, Sun Q, Pan H, Huang P, Ding J, Chen S (2017) MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease. Front Aging Neurosci 9:232. https://doi.org/10.3389/fnagi.2017.00232CrossRefPubMedPubMedCentral

19.

Cha DJ, Franklin JL, Dou Y, Liu Q, Higginbotham JN, Demory Beckler M, Weaver AM, Vickers K, Prasad N, Levy S, Zhang B (2015) KRAS-dependent sorting of miRNA to exosomes. Elife 4:e07197. https://doi.org/10.7554/eLife.07197CrossRefPubMedPubMedCentral

20.

Pan BT, Johnstone RM (1983) Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33:967–978. https://doi.org/10.1016/0092-8674(83)90040-5CrossRefPubMed

21.

Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1172. https://doi.org/10.1084/jem.183.3.1161CrossRefPubMed

22.

Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B (2001) Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 247:163–174. https://doi.org/10.1016/s0022-1759(00)00321-5CrossRefPubMed

23.

Kowal J, Tkach M, Théry C (2014) Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29:116–125. https://doi.org/10.1016/j.ceb.2014.05.004CrossRefPubMed

24.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1535750. https://doi.org/10.1080/20013078.2018.1535750CrossRefPubMedPubMedCentral

25.

Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367:eaau6977. https://doi.org/10.1126/science.aau6977CrossRefPubMedPubMedCentral

26.

Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ et al (2019) Reassessment of exosome composition. Cell 177:428–445. https://doi.org/10.1016/j.cell.2019.02.029CrossRefPubMedPubMedCentral

27.

Ghadami S, Dellinger K (2023) The lipid composition of extracellular vesicles: applications in diagnostics and therapeutic delivery. Front Mol Biosci 10:1198044. https://doi.org/10.3389/fmolb.2023.1198044CrossRefPubMedPubMedCentral

28.

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. https://doi.org/10.1038/ncb1596CrossRefPubMed

29.

Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73:1907–1920. https://doi.org/10.1016/j.jprot.2010.06.006CrossRefPubMed

30.

Gutiérrez-Vázquez C, Villarroya-Beltri C, Mittelbrunn M, Sánchez-Madrid F (2013) Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev 251:125–142. https://doi.org/10.1111/imr.12013CrossRefPubMedPubMedCentral

31.

Meldolesi J (2018) Exosomes and ectosomes in intercellular communication. Curr Biol 28:R435–R444. https://doi.org/10.1016/j.cub.2018.01.059CrossRefPubMed

32.

Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, Jen Lee M, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741. https://doi.org/10.1373/clinchem.2010.147405CrossRefPubMedPubMedCentral

33.

Mori MA, Ludwig RG, Garcia-Martin R, Brandao BB, Kahn CR (2019) Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease. Cell Metab 30:656–673. https://doi.org/10.1016/j.cmet.2019.07.011CrossRefPubMedPubMedCentral

34.

Hu G, Drescher KM, Chen XM (2012) Exosomal miRNAs: Biological properties and therapeutic potential. Front Genet 3:56. https://doi.org/10.3389/fgene.2012.00056CrossRefPubMedPubMedCentral

35.

Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS (2020) MicroRNAs: Possible regulatory molecular switch controlling the BBB microenvironment. Mol Ther Nucleic Acids 19:933–936. https://doi.org/10.1016/j.omtn.2019.12.024CrossRefPubMedPubMedCentral

36.

Ravanidis S, Bougea A, Papagiannakis N, Koros C, Simitsi AM, Pachi I, Breza M, Stefanis L, Doxakis E (2020) Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients. Ann Clin Transl Neurol 7:1594–1607. https://doi.org/10.1002/acn3.51146CrossRefPubMedPubMedCentral

37.

Gui Y, Liu H, Zhang L, Lv W, Hu X (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 206:37043–37053. https://doi.org/10.18632/oncotarget.6158CrossRef

38.

dos Santos MCT, Barreto-Sanz MA, Correia BRS, Bell R, Widnall C, Perez LT et al (2018) miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early-stage Parkinson’s disease. Oncotarget 9:17455–17465. https://doi.org/10.18632/oncotarget.24736CrossRefPubMedPubMedCentral

39.

Caldi Gomes L, Roser AE, Jain G, Pena Centeno T, Maass F, Schilde L et al (2021) MicroRNAs from extracellular vesicles as a signature for Parkinson’s disease. Clin Transl Med 11:e357. https://doi.org/10.1002/ctm2.357CrossRefPubMedPubMedCentral

40.

Tong G, Zhang P, Hu W, Zhang K, Chen X (2022) Diagnostic test to identify parkinson’s disease from the blood sera of chinese population: A cross-sectional study. Parkinsons Dis 2022:8683877. https://doi.org/10.1155/2022/8683877CrossRefPubMedPubMedCentral

41.

Cao XY, Lu JM, Zhao ZQ, Li MC, Lu T, An XS, Xue LJ (2017) MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles. Neurosci Lett 644:94–99. https://doi.org/10.1016/j.neulet.2017.02.045CrossRefPubMed

42.

Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC (2018) The serum exosome derived MicroRNA− 135a, − 193b, and − 384 were potential Alzheimer’s disease biomarkers. Biomed Environ Sci 31:87–96. https://doi.org/10.3967/bes2018.011CrossRefPubMed

43.

Barbagallo C, Mostile G, Baglieri G, Giunta F, Luca A, Raciti L, Zappia M, Purrello M, Ragusa M, Nicoletti A (2020) Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell Mol Neurobiol 40:531–546. https://doi.org/10.1007/s10571-019-00751-yCrossRefPubMed

44.

Manna I, Andrea Q, De Benedittis S, Vescio B, Iaccino E, Aldo Q (2021) Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: A pilot study. Parkinsonism Relat Disord 93:77–84. https://doi.org/10.1016/j.parkreldis.2021.11.020CrossRefPubMed

45.

He S, Huang L, Shao C, Nie T, Xia L, Cui B, Lu F, Zhu L, Chen B, Yang Q (2021) Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease. Transl Neurodegener 10:25. https://doi.org/10.1186/s40035-021-00249-yCrossRefPubMedPubMedCentral

46.

Citterio LA, Mancuso R, Agostini S, Meloni M, Clerici M (2023) Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson’s Disease. Biomolecules 13:865. https://doi.org/10.3390/biom13050865CrossRefPubMedPubMedCentral

47.

Yao YF, Qu MW, Li GC, Zhang FB, Rui HC (2018) Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci 22:5278–5283. https://doi.org/10.26355/eurrev_201808_15727CrossRefPubMed

48.

Cardo LF, Coto E, de Mena L, Ribacoba R, Moris G, Menéndez M, Alvarez V (2013) Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls. J Neurol 260:1420–1422. https://doi.org/10.1007/s00415-013-6900-8CrossRefPubMed

49.

Nie C, Sun Y, Zhen H, Guo M, Ye J, Liu Z, Yang Y, Zhang X (2020) Differential expression of plasma Exo-miRNA in neurodegenerative diseases by Next-Generation Sequencing. Front Neurosci 14:438. https://doi.org/10.3389/fnins.2020.00438CrossRefPubMedPubMedCentral

50.

Xie S, Niu W, Xu F, Wang Y, Hu S, Niu C (2022) Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson’s disease. Int J Neurosci 132:673–688. https://doi.org/10.1080/00207454.2020.1835899CrossRefPubMed

51.

Grossi I, Radeghieri A, Paolini L, Porrini V, Pilotto A, Padovani A, Marengoni A, Barbon A, Bellucci A, Pizzi M, Salvi A, De Petro G (2021) MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson’s disease: An exploratory study. Int J Mol Med 47:533–546. https://doi.org/10.3892/ijmm.2020.4806CrossRefPubMed

52.

Bhattacharyya P, Biswas A, Biswas SC (2023) Brain-enriched miR-128: Reduced in exosomes from Parkinson’s patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis. Front Cell Neurosci 16:1037903. https://doi.org/10.3389/fncel.2022.1037903CrossRefPubMedPubMedCentral

53.

Cai M, Chai S, Xiong T, Wei J, Mao W, Zhu Y, Li X, Wei W, Dai X, Yang B, Liu W (2021) Aberrant expression of circulating MicroRNA leads to the dysregulation of alpha-synuclein and other pathogenic genes in Parkinson’s disease. Front Cell Dev Biol 9:695007. https://doi.org/10.3389/fcell.2021.695007CrossRefPubMedPubMedCentral

54.

Huang Y, Liu Z, Li N, Tian C, Yang H, Huo Y, Li Y, Zhang J, Yu Z (2022) Parkinson’s disease derived exosomes aggravate neuropathology in SNCA*A53T Mice. Ann Neurol 92:230–245. https://doi.org/10.1002/ana.26421CrossRefPubMed

55.

He L, Chen Y, Lin S, Shen R, Pan H, Zhou Y, Wang Y, Chen S, Ding J (2023) Regulation of Hsa-miR-4639-5p expression and its potential role in the pathogenesis of Parkinson’s disease. Aging Cell 22:e13840. https://doi.org/10.1111/acel.13840CrossRefPubMedPubMedCentral

56.

Leggio L, Vivarelli S, L’Episcopo F, Tirolo C, Caniglia S, Testa N, Marchetti B, Iraci N (2017) microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. Int J Mol Sci 18:2698. https://doi.org/10.3390/ijms18122698CrossRefPubMedPubMedCentral

57.

Hoss AG, Labadorf A, Beach TG, Latourelle JC, Myers RH (2016) microRNA profiles in Parkinson’s disease prefrontal cortex. Front Aging Neurosci 8:36. https://doi.org/10.3389/fnagi.2016.00036CrossRefPubMedPubMedCentral

58.

Nair VD, Ge Y (2016) Alterations of miRNAs reveal a dysregulated molecular regulatory network in Parkinson’s disease striatum. Neurosci Lett 629:99–104. https://doi.org/10.1016/j.neulet.2016.06.061CrossRefPubMed

59.

Cardo LF, Coto E, Ribacoba R, Menéndez M, Moris G, Suárez E, Alvarez V (2014) MiRNA profile in the substantia nigra of Parkinson’s disease and healthy subjects. J Mol Neurosci 54:830–836. https://doi.org/10.1007/s12031-014-0428-yCrossRefPubMed

60.

Pantano L, Friedlaender MR, Escaramis G, Lizano E, Pallares-Albanell J, Ferrer I, Estivill X, Marti E (2016) Specific small-RNA signatures in the amygdala at premotor and motor stages of Parkinson’s disease revealed by deep sequencing analysis. Bioinformatics 32:673–681. https://doi.org/10.1093/bioinformatics/btv632CrossRefPubMed

61.

Briggs CE, Wang Y, Kong B, Woo TUW, Iyer LK, Sonntag KC (2015) Midbrain dopamine neurons in Parkinson׳ s disease exhibit a dysregulated miRNA and target-gene network. Brain Res 1618:111–121. https://doi.org/10.1016/j.brainres.2015.05.021CrossRefPubMedPubMedCentral

62.

Geng X, Zou Y, Li J, Li S, Qi R, Zhong L, Yu H (2023) Mesenchymal stem cell exosomes rich in miR-23b-3p affect the Wnt signaling pathway and promote neuronal autophagy to alleviate PD symptoms. Neurosci Lett 814:137437. https://doi.org/10.1016/j.neulet.2023.137437CrossRefPubMed

Title: Exosomal microRNAs in Parkinson’s disease: insights into biomarker potential and disease pathology
Publication date: 27-03-2024
Keywords: Parkinson's Disease
Biomarkers
Pathology
Published in: Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-024-07439-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Exosomal microRNAs in Parkinson’s disease: insights into biomarker potential and disease pathology

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content